Together, these findings establish a causal link between glycolytic activation and KC loss during MASLD progression, highlighting glucose metabolic pathways as potential therapeutic targets to preserve KC homeostasis and mitigate MASLD. Here, CALCA is linked to metabolic dysfunction-associated steatotic liver disease.